Literature DB >> 17192542

Clinical practice. Monoclonal gammopathy of undetermined significance.

Joan Bladé1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192542     DOI: 10.1056/NEJMcp052790

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

Review 1.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

2.  Monoclonal gammopathy of undetermined significance: significant beyond hematology.

Authors:  Steven Vanderschueren; Marieke Mylle; Daan Dierickx; Michel Delforge; Peter Verhamme; Kathelijne Peerlinck; Wouter Meersseman; Daniël C Knockaert
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

Review 3.  Serum free light chain assessment in monoclonal gammopathy and kidney disease.

Authors:  Colin A Hutchison; Kolitha Basnayake; Paul Cockwell
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 4.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

Review 5.  Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Authors:  Jonathan J Hogan; Brendan M Weiss
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-14       Impact factor: 8.237

6.  Serum free light chains and the risk of ESRD and death in CKD.

Authors:  Richard Haynes; Colin A Hutchison; Jonathan Emberson; Tanaji Dasgupta; David C Wheeler; John N Townend; Martin J Landray; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

Review 7.  Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.

Authors:  Joan Bladé; Meletios Dimopoulos; Laura Rosiñol; S Vincent Rajkumar; Robert A Kyle
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

8.  Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report.

Authors:  Waqas Jehangir; Sunil Tulpule; Federico Sanabria; Harsh Bhatt; Shoaib Zafar; Mohamed Osman; Souad Enakuaa; Abdalla Yousif
Journal:  Mol Clin Oncol       Date:  2018-07-16

9.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

10.  IgAλ monoclonal gammopathy of undetermined significance (MGUS) associated with primary selective IgM deficiency.

Authors:  Sudhir Gupta; Sudhanshu Agrawal
Journal:  Am J Clin Exp Immunol       Date:  2019-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.